<DOC>
	<DOCNO>NCT01061775</DOCNO>
	<brief_summary>The primary aim study evaluate effect Exenatide weight status ( change body mass index ) child treat craniopharyngioma develop hypothalamic obesity Children 's Hospitals Clinics Minnesota . We hypothesize Exenatide give hypothalamic obese child 6 month reduce body mass index significantly baseline .</brief_summary>
	<brief_title>Effects Exenatide Hypothalamic Obesity</brief_title>
	<detailed_description>Hypothalamic obesity individual suffer acute weight gain brain tumor treatment , involve secondary damage ventromedial nucleus hypothalamus , may lead obesity . The weight gain uncontrolled receptive diet exercise intervention . The rate long-term obesity child diagnose craniopharyngioma high 50 % . Exenatide , drug indicate diabetes , incretin mimicking agent mimic enhancement glucose-dependent insulin secretion several antihyperglycemic action incretins result weight loss give diabetic . Exenatide show potential benefit patient suffer hypothalamic obesity slow gastric empty therefore reduce food intake . Also increase glucagon-like peptide 1 ( GLP-1 ) circulation , decrease due obesity , already compromise GLP-1 receptor site hypothalamus could potentially help regulation appetite .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>&gt; /=6 month post surgical radiation chemotherapy treatment 1° craniopharyngiomas suprasellar tumor 1021 year old Ageand sexadjusted BMI &gt; /=95 % Parent sign consent patient sign assent &lt; 6 month post surgical radiation chemotherapy treatment 1° craniopharyngiomas suprasellar tumor Pregnant breastfeeding , woman plan get pregnant Renal impairment Gastroparesis Pancreatitis Diabetes &lt; 1 month post initiation Metformin treatment Prescription overthecounter weight loss medication within 3 month screen Are actively participate , participate formal weight loss program within last 3 month Have bariatric surgery</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hypothalamic Obesity</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Byetta</keyword>
	<keyword>Craniopharyngioma</keyword>
</DOC>